Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-777-6 | CAS number: 110-54-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Epidemiological data
Administrative data
- Endpoint:
- epidemiological data
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
Data source
Reference
- Reference Type:
- publication
- Title:
- Urinary excretion of 2,5-hexanedione and peripheral polyneuropathies in workers exposed to hexane.
- Author:
- Governa, M, Calisti, R, Coppa, G, Tagliavento, G, Colombi, A, Troni, W
- Year:
- 1 987
- Bibliographic source:
- J. Toxicol. Environ. Health 320:219-228
Materials and methods
- Study type:
- case control study (prospective)
- Endpoint addressed:
- neurotoxicity
- GLP compliance:
- not specified
Test material
- Reference substance name:
- N-hexane
- EC Number:
- 203-777-6
- EC Name:
- N-hexane
- Cas Number:
- 110-54-3
- Molecular formula:
- C6H14
- IUPAC Name:
- hexane
Constituent 1
Method
- Type of population:
- occupational
- Ethical approval:
- not specified
- Details on study design:
- Investigation of the correlation between electrographic changes indicative of polyneuropathy and urinary excretion of metabolites indicative of exposure to n-hexane. Forty workers were randomly chosen from four small shoe factories. All workers handled a type of glue or solvent that contained over 50% n-hexane without protective equipment for about 7 hours/day. All subjects exhibited no more than mild or nonspecific symptoms of polyneuropathy and were free of other known risk factors for nervous system impairment. A urine sample was collected at the end of a shift, and then a neurophysiological examination (MCV, SCV, and associated distal latencies [DL]) was carried out the following day. Reference values were obtained from 41 unexposed individuals.
- Exposure assessment:
- measured
- Details on exposure:
- Air concentrations were not measured. Urinary levels of metabolites were measured using acid extraction method described in Perbellini et al. (1981)
- Statistical methods:
- Urinary concentrations of the substances tested did not have a normal distribution. Therefore, correlations between urinary levels of metabolites of n-hexane and electrodiagnostic scores were tested by Kendall's t with blocking variable.
Results and discussion
- Results:
- EXPOSURE
- Number of measurements: 1 urine sample per study subject (40 subjects) at end of weekly shift
- Average concentrations: 6.80 mg/L 2,5-hexanedione in urine
- Median: 6.60 mg/L 2,5-hexanedione in urine
- Standard deviation: 4.62 mg/L 2,5-hexanedione in urine
- Extreme values: 0.50 to 19.00 mg/L 2,5-hexanedione in urine
- Date(s) of measurement(s): 2 or 4
FINDINGS: A statistically significant correlation of the electroneuromyographic scoring on the concentrations of measured metabolites in urine was observed only with 2,5-hexanedione and gamma-valerolactone, the latter of which is probably not a true metabolite of n-hexane. The results support the conclusion that polyneuropathies in shoemakers are due to 2,5-hexanedione. - Confounding factors:
- Based on case histories, seven workers were excluded who had former or actual neurological diseases different from polyneuropathy, diabetes, alchol abuse, or potentially neurotoxic medication. In the 40 workers evaluated, none had evidence of previous occupational contact to any known neurotoxic industrial substance.
Applicant's summary and conclusion
- Executive summary:
Governa et al. (1987) investigated the correlation between electrographic changes indicative of polyneuropathy and urinary excretion of metabolites indicative of exposure to n-hexane. Forty workers were randomly chosen from four small shoe factories. All workers handled a type of glue or solvent that contained over 50% n-hexane without protective equipment for about 7 hours/day. All subjects exhibited no more than mild or nonspecific symptoms of polyneuropathy and were free of other known risk factors for nervous system impairment. A urine sample was collected at the end of a shift, and then a neurophysiological examination (MCV, SCV, and associated distal latencies [DL]) was carried out the following day. Reference values were obtained from 41 unexposed individuals. The urinary concentrations n-hexane metabolites were measured in 40 workers, but only those for two of the five n-hexane metabolites were above minimum detection limits (MDLs): 2,5-hexanedione (mean, 6.80 mg/L) and (valerolactone (mean, 3.31 mg/L). A statistically significant dose-response relationship for the electroneuromyography (ENM) scores was found for 2,5 -hexanedione and valerolactone. A threshold value of 7.5 mg/L was closely related to the incidence of abnormalities. Some variation from the relationship was apparent because three workers with lower concentrations of 2.5 -hexanedione (3.0, 3.3, and 4.5 mg/L) displayed ENM changes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.